- Details
- Alicia Morgans is joined by Alan Bryce to discuss the TRITON3 trial's final overall survival data. This phase III study evaluated rucaparib against physician's choice therapy (predominantly docetaxel) in pre-chemotherapy mCRPC patients with BRCA1/2 or ATM mutations. While rucaparib previously demonstrated superior radiographic progression-free survival, including being the first therapy to outperf...
|
- Details
- In a discussion, Oliver Sartor joins Zachary Klaassen to discuss findings from the PRECISION data platform examining treatments after Lutetium-617 radioligand therapy. Dr. Sartor describes this extensive registry containing over 65,000 advanced prostate cancer patients from 500 diverse practices nationwide, including 18,000 with metastatic castration-resistant prostate cancer. Despite relatively b...
|
- Details
- Neeraj Agarwal speaks with Pedro Barata about findings regarding the under-utilization of genomic testing in metastatic castration-resistant prostate cancer. Dr. Barata shares data revealing that nearly half of patients aren't receiving homologous recombination repair (HRR) testing despite its clinical importance. Their discussion highlights that testing predominantly occurs at later disease stage...
|
- Details
- Oliver Sartor joins Zachary Klaassen to discuss the PRECISION data platform, a registry that contains over 65,000 advanced prostate cancer patients from 500 practices nationwide. Their analysis compares prompt versus deferred lutetium PSMA therapy (Pluvicto). Despite relatively short follow-up (median 17 months), findings show concordance between real-world and clinical trial outcomes. Patients re...
|
- Details
- Ramy Saleh joins Neeraj Agarwal to discuss the ACCEL trial, examining Actinium-255-PSMA-62 in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer. This trial combines an alpha-emitting radioisotope (Actinium-225) with a targeting ligand (PSMA-62) designed for better cellular internalization and tumor delivery. Unlike previous Actinium therapies with limiting toxic...
|
- Details
- Oliver Sartor is joined by Michael Morris to discuss actinium-based PSMA antibody therapy for prostate cancer. Dr. Morris explains that while small molecules like lutetium-PSMA are currently predominant, antibody approaches actually preceded them and are now regaining interest due to potential advantages, particularly reduced salivary gland toxicity. He contrasts alpha emitters like actinium with...
|
- Details
- Oliver Sartor discusses the ProstACT GLOBAL trial design, examining TLX591, a PSMA-targeting antibody bound to lutetium-177 for metastatic castration-resistant prostate cancer treatment. The phase III trial includes a 30-patient safety lead-in followed by a 400-patient randomized study comparing standard of care (ARPI switch or docetaxel) with or without TLX591. Unlike other PSMA-targeted therapie...
|
- Details
- Daniel Childs discusses real-world outcomes of lutetium-PSMA-617 treatment in prostate cancer patients with liver metastases, based on Mayo Clinic registry data. Dr. Childs presents findings showing that patients with liver metastases experience shorter overall survival (approximately 8.3 months), complete fewer treatment cycles, and demonstrate lower PSA response rates compared to those without l...
|
- Details
- Oliver Sartor and Kambiz Rahbar discuss the RaLu study examining the safety and efficacy of sequential radiopharmaceutical treatments in metastatic castration-resistant prostate cancer. The discussion highlights how lutetium-PSMA therapy can be safely administered following radium treatment, with outcomes consistent across different treatment sequences and timing intervals. They examine how these...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), experts engage in a Q&A session about PARP inhibitors in prostate cancer treatment. The discussion explores management strategies for side effects and potential treatment combinations while concluding with a debate about the ethics of control arms in clinical trials, particularly regarding ARPI switch designs in contemporary studie...
|
